BXCL501 Led to Fast, Safe, Durable Drop in Agitation in Dementia Patients

BXCL501 Led to Fast, Safe, Durable Drop in Agitation in Dementia Patients

282558

BXCL501 Led to Fast, Safe, Durable Drop in Agitation in Dementia Patients

BXCL501, BioXcel Therapeutics’ experimental therapy for the treatment of agitation associated with dementia, was found to be well-tolerated and able to rapidly and sustainably lower agitation in patients with different forms of dementia, including Alzheimer’s disease. These top-line findings from TRANQUILITY, BioXcel‘s Phase 1b/2 clinical trial (NCT04251910), are expected to support the therapy’s continued development as a treatment for agitation associated with dementia. “We are very encouraged by the promising topline results from the TRANQUILITY…

You must be logged in to read/download the full post.